Clene, Inc. (CLNN)
4.23
-0.24
(-5.37%)
USD |
NASDAQ |
Aug 28, 16:00
4.24
+0.01
(+0.24%)
After-Hours: 20:00
Clene Cash from Operations (Quarterly) : -2.578M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.578M |
| March 31, 2026 | -4.528M |
| December 31, 2025 | -4.876M |
| September 30, 2025 | -3.974M |
| June 30, 2025 | -4.729M |
| March 31, 2025 | -5.011M |
| December 31, 2024 | -4.915M |
| September 30, 2024 | -3.048M |
| June 30, 2024 | -6.358M |
| March 31, 2024 | -7.082M |
| December 31, 2023 | -7.215M |
| September 30, 2023 | -6.775M |
| June 30, 2023 | -7.020M |
| March 31, 2023 | -9.218M |
| December 31, 2022 | -7.833M |
| September 30, 2022 | -8.467M |
| June 30, 2022 | -9.670M |
| Date | Value |
|---|---|
| March 31, 2022 | -13.08M |
| December 31, 2021 | -9.571M |
| September 30, 2021 | -7.274M |
| June 30, 2021 | -8.543M |
| March 31, 2021 | -9.161M |
| December 31, 2020 | -18.14M |
| September 30, 2020 | -7.732M |
| June 30, 2020 | -2.158M |
| March 31, 2020 | -3.251M |
| December 31, 2019 | -0.1301M |
| September 30, 2019 | -0.1978M |
| June 30, 2019 | -0.1746M |
| March 31, 2019 | -0.0952M |
| December 31, 2018 | -0.0127M |
| September 30, 2018 | -0.1412M |
| June 30, 2018 | -0.0392M |
| March 31, 2018 | -0.0125M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0336M |
| Brainstorm Cell Therapeutics, Inc. | -0.895M |
| Summit Therapeutics, Inc. | -140.55M |
| Kezar Life Sciences, Inc. | -7.445M |
| Protara Therapeutics, Inc. | -15.39M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.001M |
| Cash from Financing (Quarterly) | 6.313M |
| Free Cash Flow | -16.00M |
| Free Cash Flow Per Share (Quarterly) | -0.2083 |
| Free Cash Flow to Equity (Quarterly) | -2.875M |
| Free Cash Flow to Firm (Quarterly) | -1.884M |
| Free Cash Flow Yield | -33.77% |